Umed (CEO Park Myeong-chan), a specialized urology healthcare startup, announced on the 22nd that it participated in the IBK Innovation Pavilion at CES 2026, the world's largest technology and innovation exhibition held in Las Vegas, USA. The company showcased its automated bladder irrigation system 'UroRinse™ Light', which incorporates its core technology, on the global stage and confirmed high interest from both domestic and international markets.
Umed is dedicated to developing innovative digital healthcare solutions to eliminate blind spots in urological disease management and establish a prevention-focused healthcare environment under its vision of 'Urologic Healthcare for All'. At CES 2026, it garnered significant attention by unveiling its globally targeted urological healthcare solutions for the first time and presenting a new business direction: expanding the scope of urological healthcare beyond traditional hospital-centered treatment to include prevention and active management within patients' daily lives. Beyond simply introducing its products, the company convincingly articulated a paradigm shift in managing urological diseases—essential in an aging society—and demonstrated the potential of its solutions as a new frontier in digital healthcare.
The Umed booth saw a steady stream of diverse visitors, including healthcare company representatives from around the world—including North America and Europe—medical professionals, and global investors. UroRinse™ Light, which won the CES Innovation Awards® and had its technological originality validated, instilled deep confidence in visitors by demonstrating its medical efficacy and safety through ongoing full-scale clinical trials. Visitors particularly appreciated that Umed is not only developing innovative medical devices but is also dedicated to building a solution that connects the entire evidence-based patient care process for urological diseases into a single integrated system, based on actual clinical data. They expressed high expectations for market entry, noting that this approach presents a new paradigm.
A UMED representative stated, "Participating in this year's CES served as a significant opportunity to directly confirm the concrete demand and potential for urological medical solutions within the global market, while simultaneously showcasing our technological competitiveness and vision on the world stage." Based on this meaningful achievement, Yumed plans to successfully complete its ongoing clinical trials and actively incorporate the secured objective data into product enhancement and overseas expansion strategies to accelerate its penetration of the global healthcare market.
UMED participated in the CES 2026 IBK Changgong Pavilion exhibition as a company nurtured by the 8th cohort of IBK Changgong (創工), IBK Industrial Bank of Korea's startup incubation platform.
